Triumeq Approved for the Treatment of HIV
August 22, 2014 – Triumeq (abacavir, dolutegravir, and lamivudine), manufactured by ViiV Healthcare, was approved by the Food and Drug Administration (FDA) to treat HIV-1 infection.
Triumeq is a once a day tablet that contains 600mg of abacavir (nucleoside analogue reverse transcriptase inhibitor), 50mg of dolutegravir (integrase strand transfer inhibitor) and 300mg of lamivudine (nucleoside analogue reverse transcriptase inhibitor). The cost for this treatment regimen is anticipated to be about $1,800 per month. The timing in which Triumeq is anticipated to be available on the market is not yet known.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.